Literature DB >> 15738651

Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes.

Katarzyna Kozar1, Piotr Sicinski.   

Abstract

D-type cyclins (cyclin D1, D2 and D3) and their associated cyclin-dependent kinases CDK4 and CDK6 were thought to represent important, perhaps essential components of the core cell cycle apparatus. However, recent analyses of mice lacking D-cyclins, or CDK4 and CDK6 reveal that these proteins are critically required for proliferation only in the selected cell types. Intriguingly, several compartments can develop in the absence of cyclin D-CDK4/6 activity, revealing that these cells can proliferate in a cyclin D-independent fashion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15738651     DOI: 10.4161/cc.4.3.1551

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  64 in total

1.  The ω-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation.

Authors:  Pei H Cui; Nenad Petrovic; Michael Murray
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 2.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Early and Late G1/S Cyclins and Cdks Act Complementarily to Enhance Authentic Human β-Cell Proliferation and Expansion.

Authors:  Shiwani Tiwari; Chris Roel; Rachel Wills; Gabriella Casinelli; Mansoor Tanwir; Karen K Takane; Nathalie M Fiaschi-Taesch
Journal:  Diabetes       Date:  2015-07-09       Impact factor: 9.461

4.  Developmental control of transcriptional and proliferative potency during the evolutionary emergence of animals.

Authors:  Cesar Arenas-Mena; James A Coffman
Journal:  Dev Dyn       Date:  2015-08-04       Impact factor: 3.780

Review 5.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

6.  Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.

Authors:  Solomon Tadesse; Laychiluh Bantie; Khamis Tomusange; Mingfeng Yu; Saiful Islam; Nataliya Bykovska; Benjamin Noll; Ge Zhu; Peng Li; Frankie Lam; Malika Kumarasiri; Robert Milne; Shudong Wang
Journal:  Br J Pharmacol       Date:  2018-05-08       Impact factor: 8.739

7.  Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of rats: Impact on cognitive function, synaptic plasticity and pathology.

Authors:  Ke Wu; Shoudong Li; Karthik Bodhinathan; Craig Meyers; Weijun Chen; Martha Campbell-Thompson; Lauren McIntyre; Thomas C Foster; Nicholas Muzyczka; Ashok Kumar
Journal:  Neurobiol Learn Mem       Date:  2011-09-25       Impact factor: 2.877

8.  The structure of CDK4/cyclin D3 has implications for models of CDK activation.

Authors:  T Takaki; A Echalier; N R Brown; T Hunt; J A Endicott; M E M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

9.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  A drosophila model for EGFR-Ras and PI3K-dependent human glioma.

Authors:  Renee D Read; Webster K Cavenee; Frank B Furnari; John B Thomas
Journal:  PLoS Genet       Date:  2009-02-13       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.